The role of DNA repair pathways in cisplatin resistant lung cancer

Cancer Treatment Reviews

Volumn 40, Issue 10, 2014, Pages 1161-1170

  O'Grady, Shane ^a   Finn, Stephen P ^a   Cuffe, Sinead ^a   Richard, Derek J ^b   O'Byrne, Kenneth J ^a,b   Barr, Martin P ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Cisplatin; DNA repair; Lung cancer; Resistance

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

DNA ADDUCT; DNA CROSS LINKING; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; EXCISION REPAIR; HOMOLOGOUS RECOMBINATION; HUMAN; LUNG CANCER; MISMATCH REPAIR; RECOMBINATION REPAIR; REVIEW; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; METABOLISM;

ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; HOMOLOGOUS RECOMBINATION; HUMANS; LUNG NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84923071009     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.10.003     Document Type: Review

References (118)

1. Lin X., Okuda T., Holzer A., Howell S.B. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 2002, 62(5):1154-1159.
2. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4(4):307-320.
3. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22(47):7265-7279.
4. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7(8):573-584.
5. Fuertes M.A., Alonso C., Pérez J.M. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 2003, 103(3):645-662.
6. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33(1):9-23.
7. Barr M.P., MacDonagh L., O'Byrne K.J. Markers of response to platinum-based chemotherapy in lung cancer. Lung Cancer Manage 2013, 2(3):227-239.
8. Cobo M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25(19):2747-2754.
9. Matsuoka S., Huang M., Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998, 282(5395):1893-1897.
10. Pabla N., et al. ATR-Chk2 Signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 2008, 283(10):6572-6583.
11. Chehab N.H., Malikzay A., Appel M., Halazonetis T.D. Chk2/hCds1 functions as a DNA damage checkpoint in G 1 by stabilizing p53. Genes Dev 2000, 14(3):278-288.
12. Wetzel C.C., Berberich S.J. p53 binds to cisplatin-damaged DNA. Biochim Biophys Acta (BBA) Gene Struct Expr 2001, 1517(3):392-397.
13. Gallagher W.M., Cairney M., Schott B., Roninson I.B., Brown R. Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene 1997, 14(2):185-193.
14. Kigawa J., et al. P53 gene status and chemosensitivity in ovarian cancer. Hum Cell 2001, 14(3):165-171.
15. Asada N., Tsuchiya H., Tomita K. De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line. Anticancer Res 1999, 19(6B):5131-5137.
16. Houldsworth J., et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 1998, 16(18):2345-2349.
17. Fujiwara T., et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994, 54(9):2287-2291.
18. Kanamori Y., et al. A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells. Eur J Cancer 1998, 34(11):1802-1806.
19. Rusch V., et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995, 55(21):5038-5042.
20. Hirai Y., et al. The importance of p53 and ras mutation as predictive markers for adjuvant chemotherapy in non-small-cell lung cancer. Gan To Kagaku Ryoho 2012, 39(3):381-384.
21. Kandioler-Eckersberger D., et al. The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 1999, 117(4):744-750.
22. Johnson E.A., et al. Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. Cancer Invest 2002, 20(5-6):686-692.
23. Ma X., et al. Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. Mol Oncol 2014, 8(3):555-564.
24. Iyer R.R., Pluciennik A., Burdett V., Modrich P.L. DNA mismatch repair: functions and mechanisms. Chem Rev 2005, 106(2):302-323.
25. Kunkel T.A. DNA replication fidelity. J Biol Chem 2004, 279(17):16895-16898.
26. Mello J.A., Acharya S., Fishel R., Essigmann J.M. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol 1996, 3(7):579-589.
27. Fram R.J., Cusick P.S., Wilson J.M., Marinus M.G. Mismatch repair of cis-diamminedichloroplatinum(II)-induced DNA damage. Mol Pharmacol 1985, 28(1):51-55.
28. O'Brien V., Brown R. Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis 2006, 27(4):682-692.
29. Aebi S., et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996, 56(13):3087-3090.
30. Fink D., et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996, 56(21):4881-4886.
31. Cooper W.A., et al. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions. Histopathology 2008, 52(5):613-622.
32. Hsu H.-S., et al. Promoter hypermethylation Is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clin Cancer Res 2005, 11(15):5410-5416.
33. Scartozzi M., et al. Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2006, 53(1):103-109.
34. Scartozzi M., et al. Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients. Eur J Cancer 2003, 39(8):1144-1149.
35. Kamal N.S., et al. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 2010, 16(4):1206-1215.
36. Branch P., et al. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene 2000, 19(28):3138-3145.
37. Robertson A.B., Klungland A., Rognes T., Leiros I. DNA repair in mammalian cells. Cell Mol Life Sci 2009, 66(6):981-993.
38. Wang D., et al. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer 2009, 66(3):298-304.
39. Preston T.J., Henderson J.T., McCallum G.P., Wells P.G. Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2'-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs. Mol Cancer Ther 2009, 8(7):2015-2026.
40. Kothandapani A., et al. Novel role of base excision repair in mediating cisplatin cytotoxicity. J Biol Chem 2011, 286(16):14564-14574.
41. Arora S., et al. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair 2010, 9(7):745-753.
42. Weaver D., et al. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 2005, 4(1):18.
43. Gurubhagavatula S., et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004, 22(13):2594-2601.
44. Xu C., Wang X., Zhang Y., Li L. Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2011, 14(12):912-917.
45. Yao C.Y., et al. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev 2009, 10(5):859-864.
46. Wu J., et al. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clin Cancer Res 2012, 18(14):3972-3981.
47. Chen J., Zhao Q.W., Shi G.M., Wang L.R. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies. J Zhejiang Univ Sci B 2012, 13(11):875-883.
48. Batty D.P., Wood R.D. Damage recognition in nucleotide excision repair of DNA. Gene 2000, 241(2):193-204.
49. Konishi H., et al. Effects of anticancer platinum compounds on Escherichia coli strains with normal and defective DNA repair capacity. Gann 1981, 72(4):627-630.
50. Popoff S.C., Beck D.J., Rupp W.D. Repair of plasmid DNA damaged in vitro with cis- or trans-diamminedichloroplatinum(II) in Escherichia coli. Mutat Res DNA Repair Rep 1987, 183(2):129-137.
51. Beck D.J., Popoff S., Sancar A., Rupp W.D. Reactions of the UVRABC excision nuclease with DNA damaged by diamminedichloroplatinum(II). Nucleic Acids Res 1985, 13(20):7395-7412.
52. Furuta T., et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002, 62(17):4899-4902.
53. Welsh C., et al. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004, 110(3):352-361.
54. Li Q., et al. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 1998, 273(36):23419-23425.
55. Ferry K.V., Hamilton T.C., Johnson S.W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ercc1-xpf. Biochem Pharmacol 2000, 60(9):1305-1313.
56. Dabholkar M., et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Investig 1994, 94(2):703-708.
57. Shen Y.-H., et al. Cisplatin transiently up-regulates hHR23 expression through enhanced translational efficiency in A549 adenocarcinoma cells. Toxicol Lett 2011, 205(3):341-350.
58. Zhu X.L., et al. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer. Chin Med J (Engl) 2010, 123(23):3427-3432.
59. Lai T.C., et al. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients. Oncol Rep 2011, 25(5):1243-1251.
60. Weaver D.A., et al. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 2005, 4(1):18.
61. Wang G., Dombkowski A., Chuang L., S Xu X.X. The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response. Cell Res 2004, 14(4):303-314.
62. Wang Q.-E., et al. Nucleotide excision repair factor XPC enhances DNA damage-induced apoptosis by downregulating the antiapoptotic short isoform of caspase-2. Cancer Res 2011.
63. Patrick S.M., Tillison K., Horn J.M. Recognition of cisplatin-DNA interstrand cross-links by replication protein A†. Biochemistry 2008, 47(38):10188-10196.
64. Räschle M., et al. Mechanism of replication-coupled DNA interstrand crosslink repair. Cell 2008, 134(6):969-980.
65. Sharma S., Canman C.E. REV1 and DNA polymerase zeta in DNA interstrand crosslink repair. Environ Mol Mutagen 2012, 53(9):725-740.
66. Zdraveski Z.Z., Mello J.A., Marinus M.G., Essigmann J.M. Multiple pathways of recombination define cellular responses to cisplatin. Chem Biol 2000, 7(1):39-50.
67. Takata M., et al. Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol Cell Biol 2001, 21(8):2858-2866.
68. Xu Z.Y., et al. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther 2005, 314(2):495-505.
69. Birkelbach M., et al. Detection of impaired homologous recombination repair in NSCLC cells and tissues. J Thorac Oncol 2013, 8(3):279-286.
70. Qiao G.B., et al. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 2005, 93(1):137-143.
71. Takenaka T., et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 2007, 121(4):895-900.
72. Ko J.C., et al. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. Carcinogenesis 2008, 29(7):1448-1458.
73. Ito M., et al. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005, 7(8):1044-1052.
74. Venkitaraman A.R. Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 2001, 114(20):3591-3598.
75. Chen S., Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007, 25(11):1329-1333.
76. Lee M.-N., et al. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin Cancer Res 2007, 13(3):832-838.
77. Bhattacharyya A., et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000, 275(31):23899-23903.
78. Yuan S.-S.F., et al. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 1999, 59(15):3547-3551.
79. Taron M., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004, 13(20):2443-2449.
80. Papadaki C., et al. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. J Thorac Oncol 2012, 7(4):663-671.
81. Rosell R., et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE 2009, 4(5):e5133.
82. Su C., et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol 2011, 28(4):1411-1417.
83. Bartolucci R., et al. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer 2009, 10(1):47-52.
84. Pierceall W.E., et al. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol 2012, 23(9):2245-2252.
85. Moran T., Cobo M., Domine M., et al. Interim analysis of the Spanish lung cancer group (SLCG) BRCA1-RAP80 expression customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC). J Clin Oncol 2013, 31(Suppl):LBA8002.
86. Quinn J.E., et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003, 63(19):6221-6228.
87. Yang Y., Xie Y., Xian L. Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis. J Exp Clin Cancer Res 2013, 32(1):15.
88. Olaussen K.A., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355(10):983-991.
89. Ceppi P., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006, 17(12):1818-1825.
90. Lord R.V.N., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8(7):2286-2291.
91. Azuma K., et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 2007, 98(9):1336-1343.
92. Li J., et al. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. Clin Lung Cancer 2009, 10(6):414-421.
93. Dabholkar M., et al. ERCC1 and ERCC2 expression in malignant tissues from Ovarian cancer patients. J Natl Cancer Inst 1992, 84(19):1512-1517.
94. Moore Joshi M.-B., et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005, 11(6):2215-2221.
95. Metzger R., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998, 16(1):309-316.
96. Simon G.R., et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer*. CHEST J 2005, 127(3):978-983.
97. Lee K.-H., et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 2008, 60(3):401-407.
98. Cheng J., et al. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2012, 138(2):231-238.
99. Ryu J.-S., et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004, 44(3):311-316.
100. Mazzoni F., et al. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. Lung Cancer 2013.
101. Booton R., et al. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007, 2(10):902-906.
102. Sodja E., et al. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. Eur J Cancer 2012, 48(18):3378-3385.
103. Hubner R.A., Riley R.D., Billingham L.J., Popat S. Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS ONE 2011, 6(10):e25164.
104. Roth J.A., Carlson J.J. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer 2011, 12(6):393-401.
105. Chen S., et al. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? a meta-analysis. Lung Cancer 2010, 70(1):63-70.
106. Javle M., Curtin N.J. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 2011, 105(8):1114-1122.
107. Bürkle A., et al. Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. Carcinogenesis 1993, 14(4):559-561.
108. Bryant H.E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035):913-917.
109. Albert J.M., et al. Inhibition of Poly(ADP-Ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007, 13(10):3033-3042.
110. O'Shaughnessy J., et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011, 364(3):205-214.
111. Sanofi. Sanofi provides update on Phase III studies of two investigational compounds. 2012 21/1/2014. Source:. http://www.sanofi.co.uk/l/gb/en/layout.jsp?cnt=BDFF7A0E-6FC6-4DB4-B124-09A4D9D39400.
112. Liu X., et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012, 18(2):510-523.
113. Michels J., et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013, 73(7):2271-2280.
114. Yamashita T., Miyamoto S., O'Malley B., Li D. The Role of PARP 1 for cisplatin-based chemoresistance. Otolaryngol Head Neck Surg 2010, 143(2 Suppl):P54.
115. Michels J., et al. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle 2013, 12(6):877-883.
116. Cheng H., et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis 2013, 34(4):739-749.
117. Minami D., et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res 2013, 11(2):140-148.
118. Patel A.G., et al. Failure of iniparib to inhibit Poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 2012, 18(6):1655-1662.